Glorywin Entertainment Group Inc
Glorywin Entertainment Group, Inc. is a 3D bioprinting technology research and development, anti-cancer drug research and development. The company was incorporated in 2010 and is based in Denton, Texas.
Glorywin Entertainment Group Inc (GWIN) - Net Assets
Latest net assets as of September 2024: $-53.80K USD
Based on the latest financial reports, Glorywin Entertainment Group Inc (GWIN) has net assets worth $-53.80K USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($0.00) and total liabilities ($53.80K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-53.80K |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Glorywin Entertainment Group Inc - Net Assets Trend (2011–2022)
This chart illustrates how Glorywin Entertainment Group Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Glorywin Entertainment Group Inc (2011–2022)
The table below shows the annual net assets of Glorywin Entertainment Group Inc from 2011 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-03-31 | $-99.19K | +12.88% |
| 2020-03-31 | $-113.85K | 0.00% |
| 2019-03-31 | $-113.85K | 0.00% |
| 2018-03-31 | $-113.85K | -14.79% |
| 2017-03-31 | $-99.19K | -200.46% |
| 2016-03-31 | $-33.01K | +87.77% |
| 2015-03-31 | $-270.00K | -1488.24% |
| 2013-03-31 | $-17.00K | -165.38% |
| 2012-03-31 | $26.00K | +620.00% |
| 2011-03-31 | $-5.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Glorywin Entertainment Group Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 401451900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $104.10K | % |
| Other Comprehensive Income | $-11.28K | % |
| Other Components | $3.84 Million | % |
| Total Equity | $-99.19K | 100.00% |
Glorywin Entertainment Group Inc Competitors by Market Cap
The table below lists competitors of Glorywin Entertainment Group Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TULLOW OIL
MU:TQW
|
$1.58K |
|
ARAB POLVARA SPINNING & WEAVING CO.
EGX:APSW
|
$1.58K |
|
ORIX Leasing Pakistan Limited
KAR:OLPL
|
$1.59K |
|
CAP-XX Limited
LSE:CPX
|
$1.59K |
|
MAURITIUS CHEMICAL & FERTILIZER INDUSTRY LTD
SEM:MCFI
|
$1.58K |
|
Imalliance SA
PA:MLIML
|
$1.58K |
|
RTC Group plc
LSE:RTC
|
$1.58K |
|
Ceylon Hotels Corporation PLC
CM:CHOTN0000
|
$1.58K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Glorywin Entertainment Group Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2020 to 2022, total equity changed from -113,854 to -99,186, a change of 14,668.
- Net loss of 21,539 reduced equity.
- Other factors increased equity by 36,207.
Equity Change Factors (2020 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-21.54K | -21.72% |
| Other Changes | $36.21K | +36.5% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Glorywin Entertainment Group Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-03-31 | $0.00 | $0.17 | x |
| 2022-03-31 | $0.00 | $0.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Glorywin Entertainment Group Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.39%
- • Asset Turnover: 21682.81x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (3.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 26.92% | 6.80% | 2.24x | 1.77x | $4.40K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-42.21K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-57.62K |
| 2015 | 0.00% | 34.30% | 7.77x | 0.00x | $1.35 Million |
| 2016 | 0.00% | -53.30% | 21682.81x | 0.00x | $-2.91 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.06 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.28K |
| 2022 | 0.00% | -0.39% | 21682.81x | 0.00x | $-11.62K |
Industry Comparison
This section compares Glorywin Entertainment Group Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Glorywin Entertainment Group Inc (GWIN) | $-53.80K | 26.92% | N/A | $1.58K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |